Zoetis Inc. (NYSE:ZTS) Shares Acquired by Capital Fund Management S.A.
Capital Fund Management S.A. increased its stake in Zoetis Inc. (NYSE:ZTS) by 8.9% in Q4, owning 252,536 shares valued at $41.15 million. Other hedge funds also adjusted their holdings, with Principal Financial Group increasing its stake by 17.3%. Insider transactions included sales by EVP Roxanne Lagano and Director Willie M. Reed. Zoetis shares opened at $153.85, with a market cap of $68.89 billion and a P/E ratio of 28.13. The company announced a quarterly dividend of $0.50 per share, payable on June 3rd.
Capital Fund Management S.A. lifted its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 8.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 252,536 shares of the company's stock after acquiring an additional 20,677 shares during the quarter. Capital Fund Management S.A. owned 0.06% of Zoetis worth $41,146,000 at the end of the most recent reporting period.
- Which Pet Stock Should Get Your Tail Wagging in 2024?
Other hedge funds also recently modified their holdings of the company. Howard Capital Management Group LLC lifted its stake in Zoetis by 0.8% during the third quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company's stock worth $20,489,000 after purchasing an additional 883 shares during the period. Principal Financial Group Inc. grew its holdings in Zoetis by 17.3% during the 3rd quarter. Principal Financial Group Inc. now owns 2,377,403 shares of the company's stock worth $464,497,000 after acquiring an additional 351,372 shares during the period. MML Investors Services LLC grew its holdings in shares of Zoetis by 3.2% in the 3rd quarter. MML Investors Services LLC now owns 72,982 shares of the company's stock valued at $14,259,000 after buying an additional 2,276 shares during the period. Geode Capital Management LLC grew its holdings in shares of Zoetis by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company's stock valued at $2,030,813,000 after buying an additional 185,364 shares during the period. Finally, Toronto Dominion Bank boosted its stake in Zoetis by 18.8% in the 3rd quarter. Toronto Dominion Bank now owns 233,486 shares of the company's stock worth $45,618,000 after purchasing an additional 37,013 shares during the period. Hedge funds and other institutional investors own 92.80% of the company's stock.
Insider Buying and Selling at Zoetis
In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the transaction, the executive vice president now owns 15,781 shares in the company, valued at $2,682,770. The trade was a 2.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares in the company, valued at $1,868,244.30. This trade represents a 9.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,862 shares of company stock worth $312,254 over the last quarter. Insiders own 0.16% of the company's stock.
Zoetis Price Performance
- MarketBeat Week in Review – 07/31 - 08/04
Shares of NYSE:ZTS opened at $153.85 on Thursday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The company has a market capitalization of $68.89 billion, a P/E ratio of 28.13, a P/E/G ratio of 2.78 and a beta of 0.92. The firm's 50 day simple moving average is $163.46 and its two-hundred day simple moving average is $172.01.
Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.32 billion for the quarter, compared to analysts' expectations of $2.30 billion. Research analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.
Zoetis Dividend Announcement
- Rising Dividend Make Zoetis a Doggone Winner
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.30%. The ex-dividend date is Monday, April 21st. Zoetis's dividend payout ratio (DPR) is 36.56%.
Analysts Set New Price Targets
Several equities research analysts have commented on ZTS shares. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Morgan Stanley reduced their price target on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Piper Sandler increased their price objective on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. Barclays increased their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. Finally, Stifel Nicolaus decreased their price objective on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Zoetis has a consensus rating of "Buy" and an average price target of $215.90.
Check Out Our Latest Analysis on Zoetis
Zoetis Profile
(Free Report)Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Recommended Stories
- Five stocks we like better than Zoetis
- Consumer Discretionary Stocks Explained
- First Solar Stock: What's Fueling the Early April Rally?
- Stock Trading Terms - Stock Terms Every Investor Needs to Know
- Why Analysts Boosted United Airlines Stock Ahead of Earnings
- What Are Dividend Contenders? Investing in Dividend Contenders
- Dave & Buster’s Stock: A Short-Squeeze PLAY for Q2
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Zoetis Right Now?
Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
